AD109 Cuts AHI by 59.6% in Postmenopausal Women With OSA Reena Mehra, MD

Published Date: 07 Nov 2026

In a post hoc analysis of 2 phase 3 trials, AD109 reduced hypoxic burden by 69.8% vs 20.0% with placebo in postmenopausal women with OSA.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Marstacimab Gets FDA Nod for Hemophilia A or B Without Inhibitors

2.

Study shows virtual reality headsets may help ease cancer pain

3.

Pretreatment Liver Tests Often Overlooked in CDK4/6 Therapy

4.

Some low-grade prostate cancers carry higher risks than biopsy suggests

5.

In Patients with Myeloma Who Postpone HSCT, Quadruplet Displays "Excellent Activity.".


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot